MBHYGEI@EC2612A

Haida Health Care spent HKD 4.999 million to repurchase 358,800 shares

Haidian Medical Repurchased 438,600 Shares at a Cost of HKD 5.7769 Million

CLSA Downgrades Haidian Medical's Target Price to HKD 15.90

Hugya Medical projects 76% drop in profits for 2025

Haida Healthcare Issues 2025 Fiscal Year Earnings Warning

Haida Healthcare Holdings Limited repurchased 41,800 shares at HKD 12.75 per share

Haida Healthcare Announces 10% Stock Buyback Plan, Shares Rise 10.8%

Haida Medical's Share Repurchase Drives Stock Price Up

Haida Medical Plans to Repurchase Up to 61,849,900 Shares

Founder of Haida Medical Increases Shares

CITIC Securities: Hetaia Healthcare Sees Pressured H1 2025 Earnings, Initial High-Quality Development Achieved

Haidian Medical Reports Weak H1 Profit But Improved Cash Flow

Goldman Sachs Downgrades Full Year Earnings Forecast and Target Price for Haidian Healthcare

HYGEIA HEALTH released FY2025 Q1 earnings on August 28 (BJT) with actual revenue of HKD 1.065 B and EPS of HKD 0.2141

Haidian Medical Announces First Half of 2025 Interim Results

HYGEIA HEALTH released FY2025 Semi-Annual earnings on August 28 During-Market (BJT), actual revenue HKD 2.154 B (forecast HKD 2.178 B), actual EPS HKD 0.4324 (forecast HKD 0.4378)

HYGEIA HEALTH released FY2025 Q2 earnings on August 28 During-Market (BJT), actual revenue HKD 1.089 B, actual EPS HKD 0.2185

HYGEIA HEALTH to release FY2025 Semi-Annual earnings on August 28, 2025 (BJT), forecast revenue HKD 2.18 B, EPS HKD 0.425

Haida Medical issues profit warning, expecting revenue and net profit decline in the first half of the year

CCOE

STARCOIN GROUP

ONEFORCE HLDGS

ROYAL DELUXE

STELUX HOLDINGS

TE HEALTHCARE

ASIAPAC FIN INV

WELIFE TECH

DRINDA

TIMELESS

159316

512290

159570

06078

Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

AASTOCKS

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

HANSOH PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

SKB BIO-B

ChinaAMC SSE STAR Biology and Medicine ETF

KELUN PHARMA

HENLIUS

WEIGAO GROUP

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

HYGEIA HEALTH

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

WuXi AppTec

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ANGELALIGN

Dacheng CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Medical Service ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

WUXI XDC

Ping An CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

WUXI APPTEC

Bosera Hang Seng SCHK Innovative Drug Select ETF

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

Citi released a research report, lowering the target price for HYGEIA HEALTH to 15.9 yuan, maintaining a "outperform" rating. Despite the company issuing a profit warning, expecting a 2% year-on-year decline in revenue in the second half of the year to approximately 2 billion yuan, the adjusted net profit is expected to recover to a 3% positive growth, indicating improved earnings resilience. Looking ahead to 2026, key growth drivers include expanding non-medical insurance revenue, increasing hospital utilization rates, and reducing debt ratios

In "The Big Banks," Citigroup lowered the target price for HYGEIA HEALTH to 15.9 yuan, maintaining a "Outperform" rating

Hygeia Healthcare Expects Upto 76% Lower 2025 Profit

marketscreener

Hygeia Healthcare Expects Upto 76% Lower 2025 Profit

HYGEIA HEALTH issued a profit warning, expecting a net profit decline of 66%-76% for the fiscal year 2025, ranging from 140 million to 200 million RMB, mainly due to goodwill impairment. Adjusted net profit is expected to be between 450 million and 490 million RMB, a decrease of 19%-25%. Full-year revenue is expected to be between 4 billion and 4.05 billion RMB, a decline of 9%-10%. The decrease in revenue and net profit is mainly affected by industry and macroeconomic factors, as well as increased startup costs and depreciation expenses for newly opened hospitals

"Profit Warning" HYGEIA HEALTH forecasts a 66%-76% decline in annual net profit

Hygeia Healthcare Holdings Co. Ltd. has issued a profit warning for the year ending December 31, 2025, citing a preliminary assessment of its unaudited consolidated management accounts. The company reported a decrease in capital expenditure by approximately 16% to 24% year-on-year, primarily due to the nearing completion of its last self-built hospital, Changshu Hygeia Hospital. Further declines in capital expenditure are anticipated. Full annual results are expected by the end of March 2026.

Reuters

Hygeia Healthcare Issues Profit Warning for 2025

Hygeia Healthcare Holdings Co. Ltd. has disclosed to the Hong Kong Stock Exchange the repurchase of 334,600 shares for a total of HKD 4,164,794. The shares will be held as treasury shares.

Hygeia Healthcare Files HKEX Disclosure on Repurchase of 334,600 Shares for HKD 4.16 Million

Hygeia Healthcare Holdings Co. Ltd. repurchased 238,800 shares for HKD 2.99 million, as disclosed in a filing with the Hong Kong Stock Exchange. The shares will be held as treasury shares.

Hygeia Healthcare Buys Back 238,800 Shares for HKD 2.99 Million in HKEX Filing

Hygeia Healthcare Holdings Co. Ltd. announced the repurchase of 41,800 shares at HKD 12.75 each, totaling HKD 532,950. The shares will be held as treasury shares. This disclosure was filed with the Hong Kong Stock Exchange.

Hygeia Healthcare Files Next Day Disclosure to HKEX on Repurchase of 41,800 Shares at HKD 12.75 Each

Hygeia Healthcare Holdings (SEHK:6078) shares rose 10.8% following the announcement of a 10% share buyback plan, aiming to boost net assets and earnings per share. Despite recent margin pressures and governance concerns, the buyback signals confidence and potential undervaluation. Analysts have varied opinions on the stock's fair value, with estimates suggesting it could be worth up to 52% more than its current price.

Simplywall

Hygeia Healthcare (SEHK:6078) Is Up 10.8% After Launching a 10% Share Buyback Plan – Has The Bull Case Changed?

Hygeia Healthcare Holdings (SEHK:6078) has initiated a significant share buyback, repurchasing up to 10% of its issued share capital. This move follows a period of weak market performance, with a recent 9.64% increase in share price suggesting improved investor sentiment. Despite a high price-to-earnings ratio of 15.3x, the stock may be undervalued according to a DCF model, which estimates it is trading 61% below fair value. Investors are encouraged to explore other healthcare stocks with strong fundamentals.

Hygeia Healthcare Holdings (SEHK:6078): Taking a Fresh Look at Valuation After Launching a Major Share Buyback

01057

02442

02431

02687

01788

02656

01065

01908

02637

ZHEJIANG SHIBAO(01057) rose 12.9%, with a trading turnover 326.5 Million HKD, and a year-to-date rose 58.8%. EASY SMART GP(02442) rose 12.39%, with a trading turnover 16.8 Million HKD, and a year-to-date rose 900%. MINIEYE(02431) rose 8.98%, with a trading turnover 182.9 Million HKD, and a year-to-date fell 44.5%.

Top Gainers & Losers

ZHEJIANG SHIBAO

EASY SMART GP

MINIEYE

ABLE DIGITAL

GUOTAI JUNAN I

160 HEALTH

TIANJIN CAPITAL

C&D INTL GROUP

HAIXI PHARMA

Top 10 HK Stock Gainers (12.16)

HYGEIA HEALTH announced that it has decided to utilize the repurchase authorization to periodically repurchase shares in the open market, with a total price of no less than 300 million RMB

HYGEIA HEALTH recommends share repurchase at a total price of no less than 300 million RMB

Under the influence of the DRG policy, HYGEIA HEALTH's revenue and profit have declined, with mid-term revenue expected to decrease by 15%-17% and net profit to drop by 34%-39%. The stock price has fallen from a peak of HKD 109.43 in 2021 to HKD 13.12, a decline of 87.95%. The DRG payment reform has led to a shift in the revenue model of hospitals, putting pressure on the profit margins of private hospitals

Zhitong

After the stock price has dropped by nearly 90%, is the fundamentally stable HYGEIA HEALTH on the eve of a valuation reversal?

Hygeia Healthcare Holdings (HKG:6078) has seen a significant decline in share price, dropping 71% over the past five years and 41% in the last year, despite a 48% annual increase in earnings per share (EPS) and a 24% annual revenue growth. Recent insider buying is a positive sign, but investors are advised to focus on fundamental metrics before making decisions. The stock's poor performance compared to market gains raises concerns about underlying challenges, suggesting a cautious approach for potential investors.

Positive earnings growth hasn't been enough to get Hygeia Healthcare Holdings (HKG:6078) shareholders a favorable return over the last five years

MBHYGEI@EC2612A(25910.HK)

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

In "The Big Banks," Citigroup lowered the target price for HYGEIA HEALTH to 15.9 yuan, maintaining a "Outperform" rating

Hygeia Healthcare Expects Upto 76% Lower 2025 Profit

"Profit Warning" HYGEIA HEALTH forecasts a 66%-76% decline in annual net profit

Hygeia Healthcare Issues Profit Warning for 2025